1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Valion Bio, Inc.

Valion Bio, Inc.

VBIO
Valion Bio, Inc.US flagNASDAQ
1.16
USD
-0.01
- -
2.26MMarket Cap

Total Valuation

Valion Bio, Inc. carries a market capitalization of 2.26M, placing it among publicly traded companies globally. Its enterprise value stands at 17.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.26M
Enterprise Value17.46M

Share Statistics

Valion Bio, Inc. currently has 166,076.00 shares outstanding.

Shares Outstanding166,076.00
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is -8.43, and the price-to-book ratio stands at 0.51.

PE RatioN/A
PS Ratio-8.43
PB Ratio0.51
P/TBV Ratio-1.48
P/FCF Ratio-0.09
P/OCF Ratio-0.09

Enterprise Valuation

EV / Sales4.16
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Valion Bio, Inc. maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 410.01, indicating elevated leverage, while an interest coverage ratio of -11.74 demonstrates limited ability to service its debt obligations.

Current Ratio1.11
Quick Ratio0.69
Debt / Equity410.01
Debt / EBITDA-1.11
Interest Coverage-11.74

Financial Efficiency

Return on Equity (ROE)-474.93
Return on Assets (ROA)-101.40
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.56

Stock Price Statistics

Valion Bio, Inc.'s stock has declined approximately -98.37307% over the past 52 weeks. The 50-day moving average sits at 2.97, while the 200-day moving average is 16.59.

Beta (5Y)N/A
52-Week Price Change-98.37307%
50-Day Moving Average2.97
200-Day Moving Average16.59
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Valion Bio, Inc. generated -156,000.00 in revenue and converted that into -18.75M in net income, yielding earnings per share of -176.43. EBITDA reached -15.72M, while operating income came in at -16.52M.

Revenue-156,000.00
Gross Profit-145,000.00
Operating Income-16.52M
Pretax Income-17.84M
Net Income-18.75M
EBITDA-15.72M
EBIT-16.52M
Earnings Per Share (EPS)-176.43

Balance Sheet

Valion Bio, Inc. holds 2.11M in cash and equivalents against 17.41M in total debt, resulting in a net debt position of 5.28M. Total book value stands at 4.25M, with working capital of 336,000.00 providing operational flexibility.

Cash & Cash Equivalents2.11M
Total Debt17.41M
Net Debt5.28M
Equity (Book Value)4.25M
Book Value Per Share25.57
Working Capital336,000.00

Cash Flow

Valion Bio, Inc. produced -14.57M in operating cash flow over the past twelve months. After subtracting -99,000.00 in capital expenditures, free cash flow totaled -14.67M - equivalent to -145.11 per share.

Operating Cash Flow-14.57M
Capital Expenditures-99,000.00
Free Cash Flow-14.67M
FCF Per Share-145.11

Margins

Valion Bio, Inc. operates with a gross margin of 286.54, reflecting its pricing power and cost economics. The operating margin of 10,587.18 and net profit margin of 12,019.23 provide insight into operational efficiency.

Gross Margin286.54
Operating Margin10,587.18
Pretax Margin11,437.18
Profit Margin12,019.23
EBITDA Margin10,078.85

Dividends & Yields

The company's payout ratio of 0.49 indicates the proportion of earnings distributed to shareholders.

Dividend Per ShareN/A
Dividend YieldN/A
Payout Ratio0.49
Shareholder Yield-745.26
FCF Yield-1,101.15

Stock Splits

Valion Bio, Inc.'s most recent stock split took place on August 31, 2026 with a 25:1 split ratio.

Last Split Date8/31/2026
Split Ratio25:1

Scores

Valion Bio, Inc. posts an Altman Z-Score of -5.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-5.46